Today we announced complete 36 week results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema #DME who had poor vision despite prior anti-VEGF treatment. Read the full announcement: ir.unitybiotechnology.com/ne…

We’ll be presenting first time results from the ASPIRE Phase 2b study of UBX1325 for #DME at #ARVO2025 this Wednesday, May 7. @ArshadKhanani, M.D., M.A., FASRS will host the presentation onsite at 11:00 a.m. MDT. More details: ir.unitybiotechnology.com/ne…

The Phase 2 BEHOLD study data results of UBX1325 in patients with diabetic macular edema (DME) were published in the @NEJMEvidence peer-reviewed journal. Read the full announcement and access the article: ir.unitybiotechnology.com/ne…

Today we reported Q1 2025 financial results and provided forward-looking business updates as we anticipate full 36-week Phase 2b ASPIRE data in Q2. See the earnings release: ir.unitybiotechnology.com/ne…

Our collaboration with Vestrum Health, @corevitasdata has been instrumental in driving efficiency and accelerating patient enrollment in our ASPIRE Phase 2b #DME study. Hear from Sara Huang, SVP of Clinical Operations on the impact of this partnership below.

Data from our Ph 2b ASPIRE Study found that UBX1325 generally outperformed aflibercept in patients who had moderate DME disease severity, potentially addressing a treatment breakthrough for patients who have exhausted existing therapies. Read more: bit.ly/3RjoS5R

Today we announced topline results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (#DME) who had poor vision despite prior anti-VEGF treatment. Read the full announcement: ir.unitybiotechnology.com/ne…

Today, we welcomed Yehia Hashad, MD, to our board of directors. As an experienced ophthalmologist and pharmaceutical executive, he will help guide the continued execution of our strategic vision of UBX1325 in #DME ir.unitybiotechnology.com/ne…

Today we announced our Q4 and full year 2024 financial results and business updates, including progress on our senolytic pipeline and the upcoming 24-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (#DME). See the full release: ir.unitybiotechnology.com/ne…

The growing #DME population faces significant challenges, with many experiencing suboptimal treatment response and vision decline. #UBX1325 aims to address this unmet need and improve long-term outcomes. Learn more below and stay tuned for Phase 2b ASPIRE study results.